Adynxx, Inc. (ADYX) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 San Francisco, CA, 미국. 현재 CEO는 Richard Orr.
ADYX 을(를) 보유 IPO 날짜 1998-12-18, 6 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $581.00.
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
